CorriXR Therapeutics
WILMINGTON, DE · Biotechnology · 6 employees
CorriXR Therapeutics is on the clinical frontier of gene editing as a transformative pre-clinical stage biotechnology company with a ground-breaking in vivo gene editing therapeutic platform technology. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new genetic medicines directed against drug-resistant solid tumors.
Funding history
- Series series a — $1.0M — Aug 2025
- Funding Round — $6.5M — Jan 2024
- Series seed — $6.5M — Jul 2022
Recent signals
- Jun 03, 2026: Corrixr Therapeutics Appoints Hilary M. Malone as Chief Executive Officer
- Aug 19, 2025: Raised $1.0M in Series series a
- Jan 08, 2025: CorriXR Therapeutics Names Jan Case as Chief Operating Officer
- Jan 29, 2024: Raised $6.5M
- Nov 13, 2023: CorriXR Therapeutics Announces Deborah Moorad as New Chief Executive Officer
- Sep 19, 2023: CorriXR Therapeutics Announces Deborah Moorad as Its New Chief Executive Officer
- Jul 15, 2022: Raised $6.5M in Series seed
See plans & pricing → Track CorriXR Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.